February 17, 2022
Bob Discordia Joins CaaMTech as Chief Scientific Officer
Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech
Updates
November 16, 2021
CaaMTech Teams Up with University of Wyoming to Study Psychedelics as Treatments for Addiction
Scientists will assess the potential of psychedelic compounds for treating addiction
September 15, 2021
CaaMTech Solves Crystalline Forms of Nine Serotonin Analogs
Serotonin is a tryptamine-based human neurotransmitter responsible for a variety of complex biological functions
September 8, 2021
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing …
May 3, 2021
CaaMTech CEO Chadeayne to Speak at 2021 Psychedelic Therapeutics & Drug Development Conference
Dr. Andrew Chadeayne will speak about filling the unmet need for pure, well-characterized tryptamines
April 13, 2021
CaaMTech Furthers 5-MeO-DMT Research with Orally Active 5-MeO-DPT
5-MeO-DPT is a structural analog of 5-MeO-DMT, the “God molecule”
March 22, 2021
CaaMTech Synthesizes Water-Soluble ‘Foxtrot’ Salt
5-MeO-DALT fumarate is the latest novel compound from CaaMTech and UMass Dartmouth’s Manke Lab
March 10, 2021
USPTO Publishes “Alkyl Quaternary Ammonium Tryptamines and Their Therapeutic Uses”
CaaMTech’s latest published patent application covers important, yet understudied tryptamine compounds
February 10, 2021
Patent Combining Psychedelics with Cannabinoids Allowed by USPTO
CaaMTech’s first of over one hundred patent applications is nearing the finish line
February 5, 2021
Can Synthetic Bufotenidinium Save the Toads?
CaaMTech’s synthesizes another important Bufo alvarius toad secretion compound
